Effect of hemocoagulase on the coagulation parameters, blood transfusion volume and bleeding volume of patients with severe traumatic fractures

To investigate the effect of hemocoagulase on coagulation parameters, blood transfusion volume and bleeding volume in patients with severe traumatic fractures. A total of 116 patients with severe traumatic fractures admitted to our hospital. These patients were randomly divided into the study group (hemocoagulase injection) and control group (normal saline injection), with 58 patients in each group. The bleeding time, coagulation time, perioperative bleeding volume, blood transfusion volume, hematology and coagulation parameters of the two groups were observed and compared. At 24 h post-surgery, the bleeding time and coagulation time were significantly shorter in the study group than in the control group (p < 0.05). The intraoperative bleeding volume, 24 h postoperative drainage volume, and blood transfusion volume were significantly lower in the study group than in the control group (p < 0.05). In addition, the 24 h postoperative levels of hematology parameters were significantly higher in the study group than in the control group (p < 0.05). However, coagulation parameters were similar in both groups before and at 24 h after surgery. Hemocoagulase has a better hemostatic effect and can effectively reduce perioperative bleeding without affecting the coagulation functions of patients with severe traumatic fractures. Therefore, hemocoagulase is a reliable treatment regimen in clinical practice.

Hemocoagulase; Severe traumatic fracture; Coagulation function; Blood transfusion volume; Bleeding volume

[1] Pottecher J, Lefort H, Adam P, Barbier O, Bouzat P, Charbit J, et al. Guidelines for the acute care of severe limb trauma patients. Anaesthesia Critical Care & Pain Medicine. 2021; 40: 100862.

[2] Major Extremity Trauma Research Consortium (METRC). Outcomes following severe distal tibial, ankle, and/or Mid/Hindfoot trauma: comparison of limb salvage and transtibial amputation (OUTLET). Journal of Bone and Joint Surgery. 2021; 103: 1588–1597.

[3] Bunn C, Kulshrestha S, Di Chiaro B, Maduekwe U, Abdelsattar ZM, Baker MS, et al. A leg to stand on: trauma center designation and association with rate of limb salvage in patients suffering severe lower extremity injury. Journal of the American College of Surgeons. 2021; 233: 120–129e5.

[4] Lefort H, Gil-Jardine C, Chauvin A. Guidelines for the acute care of severe limb trauma patients. European Journal of Emergency Medicine. 2021; 28: 339–340.

[5] Ho KM, Rao S, Nasim S, Rogers FB. Femoral venous catheterisation, lower limb pneumatic compression and venous thromboembolism after severe trauma: a substudy of the da Vinci trial. Anaesthesia and Intensive Care. 2021; 49: 74–76.

[6] Melendi G, Moreno RP, Hernández A, Hernández Y, Seligra C, Fain J, et al. Severe upper limb trauma related to escalator use. Pediatric case report. Archivos argentinos de pediatría. 2021; 119: e256–e260. (In Spanish)

[7] Arriaga AF, Bader AM. Severe pain after hip fracture repair in older adults: challenging a dominant narrative. Annals of Internal Medicine. 2022; 175: 1039–1040.

[8] Guo J CX, Lin Z, Jin L, Hou Z, Dong W, Zhang Y. Tight junction disruption through activation of the PI3K/AKT pathways in the skin contributes to blister fluid formation after severe tibial plateau fracture. Frontiers in Bioengineering and Biotechnology. 2022; 10: 946261.

[9] Ma R, Ren J, Zhang ZB, Men JL, Deng QJ. Effect of hemocoagulase agkistrodon on coagulation status in patients with traumatic brain injury in vitro. Zhonghua Yi Xue Za Zhi. 2021; 101: 586–590. (In Chinese)

[10] Liu Y, Li R, Tan C, Ma Y, Feng J, Xu Q, et al. Application of hemocoagulase bothrops atrox in the submucosal injection for endoscopic submucosal dissection: a preliminary trial. European Journal of Gastroenterology & Hepatology. 2021; 33: e681–e685.

[11] Rostagno C, Falchetti G, Rostagno AC, Mattesini A. TAVR in patients with hip fracture and severe aortic stenosis: how and when? Internal and Emergency Medicine. 2021; 16: 1419–1422.

[12] Costa ML, Achten J, Parsons NR. Five-year outcomes for patients sustaining severe fractures of the lower limb. The Bone & Joint Journal. 2022; 104-B: 633–639.

[13] Saito M, Moore-Lotridge SN, Uppuganti S, Egawa S, Yoshii T, Robinette JP, et al. Determining the pharmacologic window of bisphosphonates that mitigates severe injury-induced osteoporosis and muscle calcification, while preserving fracture repair. Osteoporosis International. 2022; 33: 807–820.

[14] Söreskog E, Lindberg I, Kanis JA, Åkesson KE, Willems D, Lorentzon M, et al. Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden. Osteoporosis International. 2021; 32: 585–594.

[15] Lin YC, Hsu YC, Wu WT, Lee RP, Wang JH, Chen HW, et al. The incidence of severe urinary tract infection increases after hip fracture in the elderly: a nationwide cohort study. Scientific Reports. 2021; 11: 3374.

[16] González-Marcos E, González-García E., Rodríguez-Fernández P., González-Bernal J. J., Sánchez-González E., González-Santos J. Predic-tors of moderate or severe cognitive impairment at six months of the hip fracture in the surgical patient over 65 years of age. Journal of Clinical Medicine. 2022; 11: 2608.

[17] Li J, Wong RMY, Chung YL, Leung SSY, Chow SK, Ip M, et al. Fracture-related infection in osteoporotic bone causes more severe infection and further delays healing. Bone & Joint Research. 2022; 11: 49–60.

[18] Keni R, Gourishetti K, Kinra M, Nayak PG, Shenoy R, Nandakumar K, et al. Botrops derived hemocoagulase formulation a probable agent for diabetic wound healing. 3 Biotech. 2020; 10: 443.

[19] Tang J, Kang Y, Huang L, Feng X, Wu L, Peng Y. Neuroprotective effects of hemocoagulase agkistrodon on experimental traumatic brain injury. Brain Research Bulletin. 2021; 170: 1–10.

[20] Kang BS, Kim YI, Hong S, Ban SS, Han WS, Kim BG. Decline in platelet function following administration of a snake venom-derived hemocoagulase in a patient with end-stage renal disease. Kidney Research and Clinical Practice. 2020; 39: 501–503.

[21] Torigoe K, Yamashita A, Abe S, Muta K, Mukae H, Nishino T. Effect of hemocoagulase on the prevention of bleeding after percutaneous renal biopsy. Toxins (Basel). 2022; 14: 223.

[22] Xian R, Wang C, Gong L, Hang B, Wang W, Zhang X, et al. A species-specific strategy for the identification of hemocoagulase agkistrodon halys pallas based on LC-MS/MS-MRM. Frontiers in Molecular Biosciences. 2022; 9: 831293.

[23] Nascimento da Costa T, Mota-da-Silva A, Colombini M, Moura-da-Silva AM, Medeiros de Souza R, Monteiro WM, et al. Relationship between snake size and clinical, epidemiological and laboratory aspects of Bothrops atrox snakebites in the western Brazilian Amazon. Toxicon. 2020; 186: 160–167.

[24] Lotto NP, de Albuquerque Modesto JC, Sant’Anna SS, Grego KF, Guarnieri MC, Lira-da-Silva RM, et al. The absence of thrombin-like activity in Bothrops erythromelas venom is due to the deletion of the snake venom thrombin-like enzyme gene. PLoS One. 2021; 16: e0248901.

[25] Kaido T, Yoda M, Kamijo T, Arai S, Yamauchi K, Okumura N. A novel variant fibrinogen, AalphaE11del, demonstrating the importance of AalphaE11 residue in thrombin binding. International Journal of Hematology. 2021; 114: 591–598.

[26] Reda S, Rühl H, Witkowski J, Müller J, Pavlova A, Oldenburg J, et al. PC deficiency testing: thrombin-thrombomodulin as PC activator and aptamer-based enzyme capturing increase diagnostic accuracy. Frontiers in Cardiovascular Medicine. 2021; 8: 755281.

[27] De-Simone SG, Lechuga GC, Napoleao-Pego P, Gomes LR, Provance DW Jr, Nirello VD, et al. Small angle X-ray scattering, molecular modeling, and chemometric studies from a thrombin-like (Lmr-47) enzyme of lachesis m. rhombeata venom. Molecules. 2021; 26: 3930.

[28] D’Alessandro E, Scaf B, Oerle R, Nieuwenhoven FA, Hunnik A, Verheule S, et al. Thrombin generation by calibrated automated thrombography in goat plasma: optimization of an assay. Research and Practice in Thrombosis and Haemostasis. 2021; 5: e12620.

[29] Pinheiro-Junior EL, Boldrini-França J, Takeda AAS, Costa TR, Peigneur S, Cardoso IA, et al. Towards toxin PEGylation: the example of rCollinein-1, a snake venom thrombin-like enzyme, as a PEGylated biopharmaceutical prototype. International Journal of Biological Macro-molecules. 2021; 190: 564–573.

[30] Ogawa T, Tobishima Y, Kamata S, Matsuda Y, Muramoto K, Hidaka M, et al. Focused proteomics analysis of habu snake (protobothrops flavoviridis) venom using antivenom-based affinity chromatography reveals novel myonecrosis-enhancing activity of thrombin-like serine proteases. Frontiers in Pharmacology. 2021; 12: 766406.

[31] Belo AA, Naves de Souza DL, de Melo-Braga MN, Lopes de Souza L, Molina Molina DA, Vaz de Melo PD, et al. Production of a murine mAb against Bothrops alternatus and B. neuwiedi snake venoms and its use to isolate a thrombin-like serine protease fraction. International Journal of Biological Macromolecules. 2022; 214: 530–541.

[32] Huang Y, Zhou B, Zhang D, Chen Y. Serum levels of VWF, t-PA, TNF-alpha, and ICAM-1 in patients receiving hemocoagulase combined with platelet-rich plasma during total hip replacement. Genetics Research. 2022; 2022: 2766215.

[33] Kim TO, Kim MS, Kho BG, Park HY, Kwon YS, Kim YI, et al. Paradoxical pulmonary hemorrhage associated with hemocoagulase batroxobin in a patient with hemoptysis: a CARE-compliant case report. Medicine. 2021; 100: e24040.